Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acrivon TherapeuticsACRV -0.29%35 Forward PE Ratio is 0.00 as of Aug. 13, 2026. GuruFocus rates ACRV with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 357 Biotechnology companies, Acrivon Therapeutics ranks worse than 280111.76% on this metric.
Acrivon Therapeutics (NAS:ACRV) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Acrivon Therapeutics Forward PE Ratio Related Terms
Acrivon Therapeutics Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Acrivon Therapeutics's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acrivon Therapeutics Forward PE Ratio Chart
Acrivon Therapeutics Annual Data
Trend
Forward PE Ratio
Acrivon Therapeutics Quarterly Data
Forward PE Ratio
ACRV vs SPRO, BSEM, XBIT: Forward PE Ratio Comparison
For the Biotechnology subindustry, Acrivon Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acrivon Therapeutics Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acrivon Therapeutics's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Acrivon Therapeutics's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Acrivon Therapeutics (ACRV) has a Forward PE Ratio of 0.00 as of Aug. 13, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Acrivon Therapeutics and its competitors. According to the industry distribution chart, Acrivon Therapeutics ranks #999999 out of 357 companies in the Biotechnology industry.
Is Acrivon Therapeutics' Forward PE Ratio too high?
Acrivon Therapeutics' current Forward PE Ratio is 0.00. Based on the distribution chart, Acrivon Therapeutics ranks #999999 out of 357 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Acrivon Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Acrivon Therapeutics' Forward PE Ratio compare to SPRO and BSEM?
According to the Biotechnology industry distribution chart, Acrivon Therapeutics ranks #999999 out of 357 companies for Forward PE Ratio. This places Acrivon Therapeutics in the lower half of its industry. The industry median Forward PE Ratio is 22.96. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.96, based on 357 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Acrivon Therapeutics and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acrivon Therapeutics's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acrivon Therapeutics stock overvalued right now?
Acrivon Therapeutics (ACRV) has a current Forward PE Ratio of 0.00. The current Forward PE Ratio is 0.00. Acrivon Therapeutics' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Acrivon Therapeutics (ACRV), the current Forward PE Ratio is 0.00 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
35GF Score
Get the complete analysis for ACRV
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACRV has been successfully added to your 
